Quinoxaline

Quinoxaline

SCHEMBL5358832

[NaH].c1ccc2nccnc2c1

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.55
▸ MAPT P10636 5/20 0.47
▸ NCF1 P14598 1/20 0.46
▸ KDM4E B2RXH2 4/20 0.44
▸ POLB P06746 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ USP2 O75604 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ LOXL2 Q9Y4K0 1/20 0.42
▸ LMNA P02545 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CCR1 P32246 1/20 0.40
▸ CCR5 P51681 1/20 0.40
▸ CCR8 P51685 1/20 0.40
▸ METAP1 P53582 1/20 0.40
▸ BLM P54132 1/20 0.40
▸ HIF1A Q16665 1/20 0.40
▸ DOHH Q9BU89 1/20 0.40
▸ P4HTM Q9NXG6 1/20 0.40
▸ PDE10A Q9Y233 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quinoxaline SCHEMBL30320908 0.96 ALDH1A1 (0.58) ALDH1A1MAPTNCF1KDM4EPOLB
Quinoxaline SCHEMBL5315 0.96 ALDH1A1 (0.58) ALDH1A1MAPTNCF1KDM4EPOLB
Quinoxaline SCHEMBL6928518 0.96 ALDH1A1 (0.58) ALDH1A1MAPTNCF1KDM4EPOLB
Quinoxaline SCHEMBL29355228 0.96 ALDH1A1 (0.58) ALDH1A1MAPTNCF1KDM4EPOLB
Quinoxaline SCHEMBL9171633 0.93 ALDH1A1 (0.55) ALDH1A1MAPTNCF1KDM4EPOLB
Quinoxaline SCHEMBL9171618 0.93 ALDH1A1 (0.55) ALDH1A1MAPTNCF1KDM4EPOLB
Quinoxaline SCHEMBL16053848 0.93 ALDH1A1 (0.55) ALDH1A1MAPTNCF1KDM4EPOLB
Quinoxaline SCHEMBL7329021 0.93 ALDH1A1 (0.55) ALDH1A1MAPTNCF1KDM4EPOLB
Quinoxaline SCHEMBL2431603 0.93 ALDH1A1 (0.55) ALDH1A1MAPTNCF1KDM4EPOLB
Quinoxaline SCHEMBL2359961 0.93 ALDH1A1 (0.55) ALDH1A1MAPTNCF1KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1354740-A Pharmaceutical compounds NICOX SA (FR) 2002-06-19 — — CN claimed
CN-216704355-U Enamel reaction kettle for hydrolysis of oxolinic acid 大连宝盛精细化工科技有限公司 2022-06-10 — — CN disclosed
CN-216704355-U Enamel reaction kettle for hydrolysis of oxolinic acid 大连宝盛精细化工科技有限公司 2022-06-10 — — CN disclosed
US-7202245-B2 Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines PFIZER INC. (US) 2007-04-10 — — US disclosed
EP-1613629-A1 SUBSTITUTED 4-AMINO 1,2,4 TRIAZOLO 4,3-A QUINOXALINES Pfizer Products Inc. (US) 2006-01-11 — — EP disclosed
WO-2004085439-A1 SUBSTITUTED 4-AMINO[1,2,4]TRIAZOLO[4,3-A]QUINOXALINES PFIZER PRODUCTS INC. (US) 2004-10-07 — — WO disclosed
US-20040192698-A1 Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines PFIZER INC. 2004-09-30 — — US disclosed
CN-1354740-A Pharmaceutical compounds NICOX SA (FR) 2002-06-19 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192698-A1 Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines CYP4B1, CYP3A4, CYP1B1 ALDH1A1 121/4885MAPT 4029/4885NCF1 3856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback